Novo Nordisk’s oral Wegovy treatment continues to post impressive results in 2026, sustaining momentum as the company eyes broader international expansion beyond the United States.
Chief Executive Mike Doustdar struck a confident tone with reporters, insisting that “we don’t manage the company for today’s share price,” but rather “to create long-term value.”
Doustdar pointed to the latest quarterly figures as evidence of underlying business strength, explaining that “today’s result shows that our business is performing better than expectations, which is why we raised the guidance.”
The CEO expressed firm confidence in the company’s long-term trajectory, stating: “I have no doubt that over time the fundamentals will be reflected in the shareholder value as well.”
Novo Nordisk reported net sales of 78.48 billion Danish kroner, equivalent to approximately $12.1 billion, representing 3% growth at constant currencies for the second quarter.
Adjusted sales climbed 7% when stripping out a rebate provision reversal tied to the 340B drug pricing programme, with the company attributing the underlying growth largely to GLP-1 volume increases across international markets.
Total obesity care sales jumped 16% at constant currencies to 23.15 billion kroner, or nearly $3.6 billion, underscoring the scale of consumer demand for the company’s weight-loss treatments.
Injectable Wegovy contributed 19.5 billion kroner, a 1% increase, while the oral obesity pill generated around 3.22 billion kroner, close to $500 million, marking a significant early commercial milestone for the newer treatment.
Analysts at Citi cautioned in a note to clients that the “path to uninterrupted global Wegovy pill supply” remains “not clearly defined,” flagging potential risks as launches extend beyond the US.
The Citi team warned that “with launches broadening beyond the US and demand building rapidly, manufacturing readiness will be important to sustaining momentum without constraining access or creating uneven market availability.”
The concern echoes supply chain difficulties that both Novo Nordisk and rival Eli Lilly encountered during the early rollout phases of their respective injectable GLP-1 obesity treatments.
Doustdar addressed these concerns directly during the company’s media call, stating that Novo is “making sure that we are going all in and are able to provide these medications to whoever that needs them.”
The CEO specifically referenced planned targeted launches of the oral pill in Europe, beginning in Germany, as the company prepares to broaden its geographic footprint for the new treatment.